title: After years of steady growth, winds of restraint blowing on prescription-drug industry.
abstract: Tough fiscal times are forcing cutbaks in many areas of health care, and the prescription-drug industry is no exception. The Pharmaceutical Manufacturers Association of Canada says Canada's brand-name drug companies face two major hurdles: restricted market access, as drug formularies limit the number of new drugs, and restricted price increases, as allowed by the Patented Medicine Prices Review Board and provincial formularies. The Canadian Drug Manufacturers Association, which represents Canada's generic-drug industry, says its message to physicians is that generic products are important agents of cost control and that the health care community is more aware of this than it once was. "If you don't maximize your savings while you can," cautions the association's Brenda Drinkwalter, "you'll never be able to afford the high-priced drugs of tomorrow".
authors.forename: A
authors.initials: A
authors.lastname: Robinson
mesh_terms: D003363:Cost Control; D004345:Drug Industry / Q000191:economics* / Q000639:trends; D011307:Drug Prescriptions / Q000191:economics*; D016568:Drugs, Generic / Q000191:economics; D005569:Formularies as Topic; D006801:Humans; D008389:Marketing of Health Services
chemical_list: D016568:Drugs, Generic